

FOR IMMEDIATE RELEASE

IntegraGen Reports Revenue of €6.9 million for 2018 (+ 11%) and Cash Position of €4.0 million

- Very strong increase (+29%) in sequencing services for the R&D segment
- Strong reduction in cash consumption
- Commercial launch of SIRIUS and MERCURY online genomic data interpretation software tools
- Strong commercial viability for upcoming years linked to the operational launch of the SeqOIA sequencing platform in early 2019, whose operation has been awarded to IntegraGen

Evry, France (January 9, 2018) - IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announces its unaudited annual sales revenue for 2018.

Bernard Courtieu, Chief Executive Officer, stated "*The dynamism of our growth in 2018 as well as the favorable cash position of € 4 million demonstrate the validity of our positioning and the strength of our business model. This performance positions us ideally for the years to come, especially since we will see the generation of the first income from SeqOIA in 2019. In addition, we continued our development of new offerings, in particular by now providing whole genome sequencing services as well as making globally available our genomic interpretation software tools on the Google Cloud Platform. Lastly, our very modest cash consumption in 2018 enables us to continue our current operational developments without the need for new financing in 2019.*"

	2018	2017	Difference 2018 vs. 2017
Revenues (in thousands of EUROS)	6,984	6,247	+11%
	31 December 2018	30 June 2018	31 December 2017
Cash balance (in thousands of EUROS)	4,000	3,320	4,138

2018 annual revenues increased by 11% compared to 2017, primarily driven by a 29% increase in revenue for the company's R&D services business as a result of a very significant increase in sequencing services. On the other hand, revenue for the clinical research business decreased by 17%. This decrease was primarily a result of the completion of several clinical trials and the postponement of some sequencing efforts until the establishment of the SeqOIA platform.

The market launch of the company's SIRIUS and MERCURY genomic data interpretation software tools in 2018 generated sale revenue of €239,000. MERCURY enables clinicians to identify innovative and

adapted therapeutic strategies for cancer patients with a higher probability of success due to the identification of specific genomic characteristics of a patient's tumor.

In the diagnostic activity, the company recorded revenues of €85,000 which was associated with licensing fees.

As of December 31, 2018, the company maintained a cash position of € 4.0 million, compared to € 4.1 million on 31 December 2017. This very low cash consumption was a result of efforts to improve productivity as well as various financings (loans and advances) related to the launch of the SeqOIA sequencing platform which will become operational in early 2019. As noted previously, IntegraGen has been selected by the SeqOIA Cooperative Health Group to be the provider of sequencing services for the Paris Region genomic platform within the framework of the France Genomic Medicine Plan 2025. This will result in an additional income to IntegraGen of at least € 16.4m (up to € 25m) over the next five years.

ABOUT INTEGRAGEN

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2018, IntegraGen had 44 employees and generated revenue of €6.9 million in 2018. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com



CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer

contact@integragen.com

Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER

integragen@newcap.eu

Tel.: +33 (0)1 44 71 98 53